NIPPON-SANSO-HOLDINGS
30.5.2024 10:20:31 CEST | Business Wire | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) is pleased to announce that Supagas Pty Ltd (headquarters: New South Wales, Australia; hereinafter "Supagas"), the business subsidiary company in Australia, has signed a purchase and sale agreement with Wesfarmers Chemicals, Energy and Fertilisers (hereinafter "WesCEF") to acquire the LPG sales business in Western Australia (hereinafter "WA") and Northern Territory (hereinafter "NT") of Wesfarmers Kleenheat Gas Pty Ltd (hereinafter "Kleenheat"), which handles the LPG business of WesCEF.
-
Background and purpose of the acquisition
In addition to its core business of supplying LPG, Supagas is already steadily expanding its business in the supply of industrial gases and other products through 48 offices and over 200 retails in New South Wales and Queensland.
Supagas has been aiming to acquire an established sales network in northern and western Australia and expand its sales channels. The recent proposal from Wesfarmers for the sale of Kleenheat's assets matches Supagas' business expansion plans, which led to the conclusion of this agreement.
Through the acquisition of Kleenheat's LPG sales business, which has a stable supply of LPG to both residential and industrial demand in WA and NT for over 65 years, Supagas will expand its sales channels into northern and western Australia, realize synergies not only with LPG but also with its existing industrial gas business, and achieve sustainable boost in profitability.
-
Overview of the acquisition
Business: Kleenheat's LPG sales business in WA and NT
Business assets: LPG supply facilities (land, buildings) and related facilities (including supply facilities and vehicles)
-
Future plans
The purchase is expected to be completed by the end of August, subject to approval by Australian Competition and Consumer Commission (ACCC).
The Nippon Sanso Holdings Group is the world's fourth-largest supplier of industrial, electronic, and medical gases, operating in four geographic regions - Japan, U.S., Europe and Asia & Oceania - covering over 30 countries and regions. In addition, the Thermos business supplies THERMOS branded products to more than 120 countries worldwide. Since its foundation as Nippon Sanso Ltd. in 1910, the group stands for creating social value through innovative gas solutions that increase industrial productivity, enhance human well-being and contribute to a more sustainable future. With more than 19,000 employees, together, we are “The Gas Professionals” and we all have the same goal: “Making life better through gas technology”
Important Notice – Trading of Nippon Sanso Holdings Corporation Common Stock, Disclaimer Regarding Unsponsored American Depository Receipts
Nippon Sanso Holdings Corporation ("NSHD”) encourages anyone interested in buying or selling its common stock to do so on the Tokyo Stock Exchange, which is where its common stock is listed and primarily trades. NSHD’s disclosures are not intended to facilitate trades in, and should not be relied on for decisions to trade, unsponsored American Depository Receipts (“ADRs”).
NSHD has not and does not participate in, support, encourage, or otherwise consent to the creation of any unsponsored ADR programs or the issuance or trading of any ADRs issued thereunder in respect of its common stock. NSHD does not represent to any ADR holder, bank or depositary institution, nor should any such person or entity form the belief, that (i) NSHD has any reporting obligations within the meaning of the U.S. Securities Exchange Act of 1934 (“Exchange Act”) or (ii) NSHD’s website will contain on an ongoing basis all information necessary for NSHD to maintain an exemption from registering its common stock under the Exchange Act pursuant to Rule 12g3-2(b) thereunder.
To the maximum extent permitted by applicable law, NSHD and its affiliates disclaim any responsibility or liability to ADR holders, banks, depositary institutions, or any other entities or individuals in connection with any unsponsored ADRs representing its common stock.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529523496/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat
Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 07:30:00 CEST | Press release
Organic revenue growth sequential improvement;2026 outlook confirmed Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8
AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 07:00:00 CEST | Press release
Third annual edition of The CEO Response finds leaders prioritizing AI and business alliances as demands on CEO leadership grow Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much fas
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 07:00:00 CEST | Press release
Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the development of new technologies and expanded clinical indications, with data to be presented from four studies across the chin, jawline, temples, and lower face Several Meet-the-Expert sessions and a symposium on the AART™ of Body, which highlights new expanded indications for Sculptra in the gluteal area, posterior thighs, and décolletage, follows Sculptra’s recent approval for use on the body in the United Arab Emirates (UAE)9 Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company
Sihoo præsenterer næste generation af ergonomiske kontorløsninger på ORGATEC 202620.10.2026 20:12:00 CEST | Pressemeddelelse
Med ORGATEC 2026 lige om hjørnet vil Sihoo, specialist i ergonomiske sidde løsninger, præsentere sine næste generations løsninger til arbejdspladsen i hal 8.1, stand A-060 og B-061. I tråd med messens tema, »Fra rum til relationer: design af rum i en verden i konstant forandring«, vil Sihoo demonstrere, hvordan adaptivt ergonomisk design understøtter skiftende siddestillinger og nye behov på moderne arbejdspladser. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261020048673/da/ Sihoo på ORGATEC 2026 i Köln En oplevelseszone baseret på forskellige arbejdsscenarier Sihoos stand har et åbent layout, hvor en orange-hvid farvepalet kombineres med loftskonstruktioner i flere niveauer, halvgennemsigtige skillevægge og integreret belysning. Arbejdsstationer med højdejusterbare skriveborde og skærme samt siddeområder til samarbejde genskaber velkendte kontormiljøer og viser, hvordan ergonomiske stole passer ind på moderne arbejdspl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
